Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Tony L. Alford | LCU Lion Copper Corp. | 13D/A | 32.9% | Apr 8, 2024 | 2y |
| Dunde Yu | TOUR Tuniu Corp | 13D/A | 8.3% | Apr 5, 2024 | 2y |
| Fang Zheng | ZOOZ ZOOZ Strategy Ltd. | 13D | 21.67% | Apr 4, 2024 | 2y |
| JANUS HENDERSON GROUP PLC | ORKA Oruka Therapeutics, Inc. | 13G | 7.4% | Apr 3, 2024 | 2y |
| Millennium Management LLC | CMPS COMPASS Pathways plc | 13G | 5.7% | Apr 2, 2024 | 2y |
| WOLVERINE ASSET MANAGEMENT LLC | DSAQ Direct Selling Acquisition Corp. | 13G/A | 2.91% | Apr 1, 2024 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | CRVO CervoMed Inc. | 13G | 9.99% | Apr 1, 2024 | 2y |
| Dominion Capital LLC | HUBC Hub Cyber Security Ltd. | 13D/A | 0.4% | Apr 1, 2024 | 2y |
| Granahan Investment Management, LLC | INDI indie Semiconductor, Inc. | 13G/A | 11.78% | Mar 31, 2024 | 2y |
| WOLVERINE ASSET MANAGEMENT LLC | ZPTA Zapata Quantum, Inc. | 13G/A | 0% | Mar 28, 2024 | 2y |
| James Michael McCrory | IBAC IB Acquisition Corp. | 13D | 6.6% | Mar 28, 2024 | 2y |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | BNTC Benitec Biopharma Inc. | 13G/A | 9.99% | Dec 31, 2023 | 2y |
| F9 Investments, LLC (Single Member LLC with Thomas D. Sullivan Single Member) | LL LL Flooring Holdings, Inc. | 13D/A | 8.8% | Aug 17, 2023 | 2y |
| LONGVIEW ASSET MANAGEMENT, LLC | GD General Dynamics Corp | 13D/A | 10.3% | Apr 10, 2024 | 2y |
| TAKEDA PHARMACEUTICAL CO LTD | PHAT Phathom Pharmaceuticals, Inc. | 13D/A | 4.8% | Apr 9, 2024 | 2y |
| JOHNSON & JOHNSON | CTNM Contineum Therapeutics, Inc. | 13G | 10.7% | Apr 9, 2024 | 2y |
| Insight Venture Partners X, L.P. | S SentinelOne, Inc. | 13D/A | 8.2% | Apr 9, 2024 | 2y |
| GAMCO INVESTORS, INC. ET AL | KAMN Kaman Corp | 13D/A | 8.11% | Apr 9, 2024 | 2y |
| Cloud Alliance Inc | QH QUHUO Ltd | 13D/A | 25.96% | Apr 9, 2024 | 2y |
| Murat Kalayoglu | RNAC Cartesian Therapeutics, Inc. | 13D/A | 19.9% | Apr 8, 2024 | 2y |
| Weinzierl John A | BSIN Big Sky Industrial Inc. | 13D/A | 31% | Apr 8, 2024 | 2y |
| New Enterprise Associates 15, L.P. | NEUE NeueHealth, Inc. | 13D/A | 56.6% | Apr 8, 2024 | 2y |
| Michael Singer | RNAC Cartesian Therapeutics, Inc. | 13D/A | 4.3% | Apr 8, 2024 | 2y |
| FAIRFAX FINANCIAL HOLDINGS LTD/ CAN | CCAP Crescent Capital BDC, Inc. | 13G/A | 4.9% | Apr 8, 2024 | 2y |
| Bluescape Riley Exploration Holdings LLC | REPX Riley Exploration Permian, Inc. | 13D/A | 21.11% | Apr 8, 2024 | 2y |
| Riley Exploration Group, LLC | REPX Riley Exploration Permian, Inc. | 13D/A | 12.35% | Apr 8, 2024 | 2y |
| Saba Capital Management, L.P. | PEO Adams Natural Resources Fund, Inc. | 13D/A | 8.23% | Apr 8, 2024 | 2y |
| Mitsui & Co., Ltd. | ATLX Atlas Lithium Corp | 13D | 12.8% | Apr 4, 2024 | 2y |
| Peter A. Appel | MOVE Corvex, Inc. | 13G | 9.99% | Apr 4, 2024 | 2y |
| Y.D. More Investments Ltd | ZOOZ ZOOZ Strategy Ltd. | 13G | 11.81% | Apr 4, 2024 | 2y |
| Kit Yee Sze | NIVF NewGenIvf Group Ltd | 13G | 5.4% | Apr 3, 2024 | 2y |
| Kenneth R. Lehman | BRBS Blue Ridge Bankshares, Inc. | 13D | 5.2% | Apr 3, 2024 | 2y |
| Wing Fung Alfred Siu | NIVF NewGenIvf Group Ltd | 13D | 40.5% | Apr 3, 2024 | 2y |
| Castle Creek Capital Partners VIII, LP | BRBS Blue Ridge Bankshares, Inc. | 13D | 2.6% | Apr 3, 2024 | 2y |
| Bank of New York Mellon Corp | AFK VanEck ETF Trust | 13G/A | 11.85% | Mar 31, 2024 | 2y |
| 1607 Capital Partners, LLC | MGF Aberdeen Government Markets Income Fund | 13G/A | 7.57% | Mar 31, 2024 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | GLUE Monte Rosa Therapeutics, Inc. | 13G/A | 10.2% | Mar 31, 2024 | 2y |
| JONATHAN KOLBER | REAX Real REMAX Group Inc. | 13G | 6.07% | Mar 31, 2024 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | BPMC Blueprint Medicines Corporation | 13G/A | 10.2% | Mar 31, 2024 | 2y |
| Bank of New York Mellon Corp | NCLO NuShares ETF Trust | 13G/A | 10.22% | Mar 31, 2024 | 2y |
| STATE STREET CORP | REPL Replimune Group, Inc. | 13G/A | 10.57% | Mar 31, 2024 | 2y |
| GLAZER CAPITAL, LLC | AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares | 13G/A | 7.21% | Mar 31, 2024 | 2y |
| Wealthspring Capital LLC | KDK Kodiak AI, Inc. | 13G/A | 10.2% | Mar 31, 2024 | 2y |
| CITIGROUP INC | BVN Buenaventura Mining Co Inc | 13G/A | 0.2% | Mar 31, 2024 | 2y |
| STATE STREET CORP | EDIT Editas Medicine, Inc. | 13G/A | 10.71% | Mar 31, 2024 | 2y |
| RIVERNORTH CAPITAL MANAGEMENT, LLC | BRAC Broad Capital Acquisition Corp Common Stock | 13G | 10.63% | Mar 31, 2024 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | REPL Replimune Group, Inc. | 13G/A | 10.7% | Mar 31, 2024 | 2y |
| PRICE T ROWE ASSOCIATES INC /MD/ | SMHI SEACOR Marine Holdings Inc. | 13G/A | 4.7% | Mar 31, 2024 | 2y |
| STATE STREET CORP | CCCC C4 Therapeutics, Inc. | 13G | 10.43% | Mar 31, 2024 | 2y |
| EARNEST PARTNERS LLC | FCFS FirstCash Holdings, Inc. | 13G/A | 5.1% | Mar 31, 2024 | 2y |